Adding Capsugel to Create an Integrated Service Provider for the Healthcare Continuum Audited


In 2017 Lonza completed the acquisition of U.S.-based Capsugel. Capsugel – now a Lonza company – designs, develops and manufactures a wide range of innovative dosage forms for more than 4,000 customers in the biopharmaceutical and consumer health and nutrition industries in more than 100 countries.


The acquisition of Capsugel accelerates Lonza’s strategy to grow and deliver value along the healthcare continuum by complementing our existing offerings and by opening up new market opportunities in the pharma and consumer health industries. This transformational step positions Lonza as a unique integrated global leader serving those industries.

With Capsugel’s additional sales, 66% of Lonza’s total revenues are now derived from providing profitable solutions to customers in the pharma and consumer healthcare and nutrition industries.

After the successful closing of the acquisition of Capsugel on 5 July 2017, the post-deal integration began immediately. Lonza puts a strong focus on business continuity while the integration successfully proceeded as planned. All integration workstreams made great progress during 2017 on the journey to bring our two world-class companies together; and at the beginning of 2018, we started to work as one company. Colleagues across the globe have started to build relationships, share expertise and work as one team to bring quality, innovation and excellence to customers – from ingredient sourcing to finished dosage forms.

To energize the one-team spirit, Lonza leaders have been visiting Capsugel sites around the world to meet with teams, to welcome colleagues into the Lonza family and to raise any issues and capture potential opportunities. Lonza and Capsugel employees are committed to the common path of offering high-quality products and services along the healthcare continuum.